FDA
-
-
-
-
-
-
-
Ascentage Pharma reports phase III data for leukemia drug candidate
-
-
-
-
-
-
-
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
-
-
-
-
-
-
-
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
-
-
-
-
-
-
-
Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement
-
-
-
-
-
-
-
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
-
-
-
-
-
-
-
Ascentage Pharma (AAPG) Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

